We completed the in vivo studies with an analysis of serum levels of glucose, insulin, leptin and CCL2 in treated and untreated tumor bearers with different body weights, to investigate whether body weight and inhibition of leptin signaling might modulate the systemic levels of these important metabolic parameters. Here, LEP is linked to neoplasm.